Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials

被引:17
|
作者
Maguire, Maureen G. [1 ]
Ying, Gui-shuang [1 ]
Jaffe, Glenn J. [2 ]
Toth, Cynthia A. [2 ]
Daniel, Ebenezer [1 ]
Grunwald, Juan [1 ]
Martin, Daniel F. [3 ]
Hagstrom, Stephanie A. [3 ]
机构
[1] Univ Penn, Dept Ophthalmol, 3535 Market St,Ste 700, Philadelphia, PA 19104 USA
[2] Duke Univ, Dept Ophthalmol, Durham, NC USA
[3] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA
基金
美国国家卫生研究院;
关键词
COMPLEMENT FACTOR-H; RETINAL ANGIOMATOUS PROLIFERATION; POLYPOIDAL CHOROIDAL VASCULOPATHY; GENOME-WIDE ASSOCIATION; BEVACIZUMAB; GENOTYPE; Y402H; RISK; CFH; RANIBIZUMAB;
D O I
10.1001/jamaophthalmol.2016.0669
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
IMPORTANCE Single-nucleotide polymorphisms (SNPs) associated with the CFH, ARMS2, C3, LIPC, CFB, and C2 genes are associated with age-related macular degeneration (AMD); however, the association of these SNPs with angiographic features of neovascular AMD has been inconsistent in previous studies, and to date, no studies have addressed their association with features on optical coherence tomography. OBJECTIVE To evaluate the influence of genotype of SNPs previously associated with AMD on the phenotype of neovascular lesions. DESIGN, SETTING, AND PARTICIPANTS Participants for this cross-sectional study were recruited from the 1185 patients enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), a randomized clinical trial. Eligibility criteria for CATT specified that eyes have choroidal neovascularization and visual acuity between 20/25 and 20/320. A subgroup of 835 patients provided blood samples from July 2010 through September 2011 and were genotyped for the SNPs rs1061170 (CFH), rs10490924 (ARMS2), rs2230199 (C3), rs10468017 (LIPC), rs4151667 (CFB), rs547154 (C2) using TaqMan SNP genotyping assays. Data analysis was initiated in November 2013 and completed in January 2016. MAIN OUTCOMES AND MEASURES Pretreatment ocular characteristics on fluorescein angiography (lesion type, area of neovascularization and total lesion, retinal angiomatous proliferation) and on time-domain optical coherence tomography (presence of intraretinal, subretinal, and subretinal pigment epithelium fluid; thickness at the foveal center of the retina, subretinal fluid, and subretinal tissue complex), visual acuity, and age. RESULTS A total of 835 (73%) of 1150 CATT patients were genotyped. Mean age decreased with the number of risk alleles for CFH (P < .001), ARMS2 (P < .001), and C3 (P = .005). The following results were found as the number of risk alleles increased from 0 to 1 to 2. For CFH, mean total thickness decreased from 476 to 476 to 434 mu m (P = .01; adjusted for age, sex, and smoking status). For ARMS2, the mean area of the total lesion increased from 2.0 to 2.8 to 2.4 mm(2) (P = .03), the proportion with retinal angiomatous proliferation lesions increased from 8% to 10% to 12%(P = .05), and the proportion with intraretinal fluid increased from 72% to 71% to 82% (P = .008). For C3, the proportion with intraretinal fluid decreased from 78% to 69% to 64%(P = .001), and the mean retinal thickness decreased from 225 to 207 to 197 mu m (P = .02). CONCLUSIONS AND RELEVANCE CFH, ARMS2, and C3 were associated with specific features of neovascularization at the time patients were enrolled in CATT. Previously identified associations of ARMS2 and CFH with type of choroidal neovascularization on fluorescein angiography were not confirmed. New associations with OCT features identified in CATT need confirmation to establish whether a true association exists. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00593450.
引用
收藏
页码:674 / 681
页数:8
相关论文
共 50 条
  • [41] Age-related macular degeneration
    Gottlieb, JL
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (18): : 2233 - 2236
  • [42] Age-related macular degeneration
    Seigel, Daniel
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (16): : 1735 - 1735
  • [43] Age-related macular degeneration
    Dalibon, Pierre
    ACTUALITES PHARMACEUTIQUES, 2014, 53 (539): : 31 - 36
  • [44] Age-related macular degeneration
    Eisenstein, Michael
    NATURE, 2021, 600 (7887) : S1 - S1
  • [45] Age-related macular degeneration
    Mitchell, Paul
    Liew, Gerald
    Gopinath, Bamini
    Wong, Tien Y.
    LANCET, 2018, 392 (10153): : 1147 - 1159
  • [46] Age-Related Macular Degeneration
    Randolph, Susan A.
    WORKPLACE HEALTH & SAFETY, 2014, 62 (08) : 352 - 352
  • [47] Age-Related Macular Degeneration
    Mehta, Sonia
    PRIMARY CARE, 2015, 42 (03): : 377 - +
  • [48] Age-related macular degeneration
    Soubrane, G
    Kuhn, D
    Coscas, G
    M S-MEDECINE SCIENCES, 1998, 14 (12): : 1378 - 1381
  • [49] Age-related macular degeneration
    Steinberg, Johannes
    Uibel, Stefanie
    Berndt, Thomas
    Mller, Daniel
    Quarcoo, David
    Groneberg, David A.
    ZENTRALBLATT FUR ARBEITSMEDIZIN ARBEITSSCHUTZ UND ERGONOMIE, 2011, 61 (08): : 270 - 286
  • [50] Age-related macular degeneration
    Vinding, T
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 1995, 73 : 3 - +